Suffering Eleven Bio gets a delisting notice from Nasdaq

After back-to-back clinical disasters pushed Eleven Biotherapeutics ($EBIO) into penny stock territory, Nasdaq says it's time to get squared away or move off the exchange. The Cambridge, MA-based biotech addressed the delisting notice from Nasdaq in an SEC filing, noting that its stock is trading under $1 a share and that stockholders' equity did not comply with the minimum stockholders' equity requirement of $5,000,000. The biotech now has 180 days to regain compliance with Nasdaq rules. SEC filing

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.